var data={"title":"Diflucortolone (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diflucortolone (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/762611?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=diflucortolone-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Diflucortolone (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834846\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Nerisone Cream;</li>\n      <li>Nerisone Oily Cream;</li>\n      <li>Nerisone Ointment</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834848\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834656\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute and chronic skin disease:</b> Topical: Apply a thin layer using only enough to cover affected area 1 to 2 times daily. Lack of improvement or worsening of condition after 2 to 4 weeks of therapy may necessitate further evaluation. Maximum duration of therapy: 4 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834655\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute and chronic skin disease:</b> Children &gt;1 year and Adolescents: Topical: Apply the least amount for the shortest duration of time needed to achieve desired therapeutic effect. May apply a thin layer using only enough to cover affected area 1 to 2 times daily. Lack of improvement or worsening of condition after 2 to 4 weeks of therapy may necessitate further evaluation Maximum duration of therapy: 4 weeks </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834657\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute and chronic skin disease:</b> Topical: Apply the least amount for the shortest duration of time needed to achieve desired therapeutic effect. Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834658\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the manufacturer recommends applying the least amount for the shortest period of time required to achieve desired therapeutic effect.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834659\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the manufacturer recommends applying the least amount for the shortest period of time required to achieve desired therapeutic effect. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834847\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834781\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, External, as valerate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nerisone: 0.1% (30 g) [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oily Cream, External, as valerate [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nerisone: 0.1% (30 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ointment, External, as valerate [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nerisone: 0.1% (30 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834780\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834777\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For topical use only. Rub a thin layer in gently using only enough to cover affected area. Avoid use of occlusive dressings. Do not apply in or near the eye or on other mucous membranes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834641\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute and chronic skin disease:</b> Treatment of acute and chronic skin diseases responsive to the anti-inflammatory, antipruritic, and antiallergic effects of topical corticosteroids.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27427820\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Reactions listed are based on reports from other topical steroids and may not be specifically reported for diflucortolone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Localized burning, steroid withdrawal syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acneiform eruption, alopecia, atrophic striae, contact dermatitis, dermatitis, dyschromia, epidermal thinning, erythema, folliculitis, hair breakage, hypertrichosis, miliaria, perioral dermatitis, pruritus, pustular psoriasis, skin atrophy, skin pain, skin rash, telangiectasia, urticaria, wrinkling of skin, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Cushingoid appearance, decreased plasma cortisol, glycosuria, hpa-axis suppression, hyperglycemia, obesity, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Local hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Immunosuppression (underlying symptom exacerbation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Secondary infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site irritation, application site pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Decreased linear skeletal growth rate, osteoporosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Cataract, glaucoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Failure to thrive</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834644\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to diflucortolone, any component of the formulation, or other corticosteroids; infants &lt;1 year of age; viral (eg, herpes, varicella, vaccinia) lesions of the skin, bacterial or fungal skin infections, parasitic infections, skin manifestations relating to tuberculosis or syphilis, eruptions following vaccinations; rosacea; pruritus without inflammation; perianal and genital pruritus; perioral dermatitis; acne vulgaris; ophthalmic application</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834645\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Patients receiving large doses of potent topical steroids should be periodically evaluated for HPA axis suppression using urinary free cortisol and ACTH stimulation tests. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully by reducing the frequency of application or substitution of a less potent steroid. Recovery is usually prompt and complete upon drug discontinuation, but may require supplemental systemic corticosteroids if signs and symptoms of steroid withdrawal occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact dermatitis: Allergic contact dermatitis may occur; it is usually diagnosed by failure to heal rather than clinical exacerbation. Patch testing may be used to confirm the diagnosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Localized hypersensitivity reactions may occur; discontinue use if hypersensitivity occurs and treat appropriately. Allergic contact dermatitis is usually diagnosed by failure to heal rather than clinical exacerbation. Patch testing may be used to confirm the diagnosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Discontinue use if concomitant skin infection occurs and treat appropriately. Exposure to varicella zoster (chickenpox) should be avoided; corticosteroids should not be used to treat ocular herpes simplex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports) (Goedert 2002); if noted, discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psoriasis: Use with caution and monitor carefully; rebound relapses, development of tolerances, risk of generalized pustular psoriasis, and development of localized or systemic toxicity due to impaired skin barrier have been observed. Discontinue use with significant irritation and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Special populations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Other warnings/precautions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Avoid use of occlusive dressings; may increase systemic exposure and risk of adrenal suppression and other systemic effects. Use with caution in patients with stasis dermatitis or other skin diseases associated with impaired circulation. Application near chronic leg ulcers may increase risk of localized hypersensitivity reactions and infection. Use with caution near the eyes (do not apply to the eyes), and on the face, groin and axilla. Monitor for skin atrophy and discontinue use if observed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26868957\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26868954\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=99273&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834642\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids (including diflucortolone) in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such as psoriasis or atopic dermatitis in pregnant women; high potency corticosteroids are not recommended during the first trimester. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women (Bae 2011; Koutroulis 2011; Leachman 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834643\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Corticosteroids are present in human milk. It is not known if systemic absorption following topical administration results in detectable quantities in human milk. Do not apply topical corticosteroids to breasts; hypertension was noted in a breastfeeding infant exposed to a topical corticosteroid while breastfeeding (Leachman 2006).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a breastfeeding infant (eg, growth suppression, interfere with endogenous corticosteroid production) and therefore recommends that caution be exercised when administering diflucortolone to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834779\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Adrenal suppression with extensive/prolonged use (ACTH stimulation test); response to treatment; growth in children</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834648\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A2 inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Diflucortolone has intermediate range potency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834650\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Percutaneous absorption is variable and dependent upon many factors including vehicle used, integrity and thickness of epidermis, surface area of application, and use of occlusive dressings (not recommended)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism:\tHepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine and feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27001411\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Claral (ES);</li>\n      <li>Cortical (IT);</li>\n      <li>Dermaval (IT);</li>\n      <li>Dervin (IT);</li>\n      <li>Diflucor (IN);</li>\n      <li>Difuco (KR);</li>\n      <li>Isolone (KR);</li>\n      <li>Neriderm (IL);</li>\n      <li>Neriforte (AT);</li>\n      <li>Nerilon (ID);</li>\n      <li>Nerisona (AT, BE, BR, CR, DE, DO, GT, HN, ID, IT, KR, NI, PA, PT, SV);</li>\n      <li>Nerisone (AE, EG, FR, GB, HK, NZ, PK, ZA);</li>\n      <li>Nerisone Forte (GB);</li>\n      <li>Temetex (IT, TR);</li>\n      <li>Valeron (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the medical board of the National Psoriasis Foundation. <i>J Am Acad Dermatol</i>. 2012;67(3):459-477.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diflucortolone-united-states-not-available-drug-information/abstract-text/22018758/pubmed\" target=\"_blank\" id=\"22018758\">22018758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst</i>. 2002;94(22):1712-1718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diflucortolone-united-states-not-available-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koutroulis I, Papoutsis J, Kroumpouzos G. Atopic dermatitis in pregnancy: current status and challenges. <i>Obstet Gynecol Surv</i>. 2011;66(10):654-663.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diflucortolone-united-states-not-available-drug-information/abstract-text/22112526/pubmed\" target=\"_blank\" id=\"22112526\">22112526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diflucortolone-united-states-not-available-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nerisone (diflucortolone valerate) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc.; January 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 99273 Version 28.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F26834846\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F26834848\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F26834656\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F26834655\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F26834657\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F26834658\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F26834659\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F26834847\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F26834781\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F26834780\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F26834777\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F26834641\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F27427820\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F26834644\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F26834645\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F26868957\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F26868954\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F26834642\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F26834643\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F26834779\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F26834648\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F26834650\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F27001411\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/99273|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=diflucortolone-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Diflucortolone (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}